Please ensure Javascript is enabled for purposes of website accessibility

COVID-19 Clobbers Align Technology's Q1 Results

By Keith Speights – Apr 30, 2020 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The orthodontic device maker reported sharp sequential revenue and earnings declines in the first quarter because of the COVID-19 pandemic.

No one expected that Align Technology's (ALGN -0.48%) first-quarter results would be great. The orthodontic device maker began to reset expectations in late January when it provided Q1 guidance in its fourth-quarter update that was well below what Wall Street had previously estimated.

Align announced its Q1 results after the market closed on Wednesday. And the numbers were even grimmer than anticipated. Here are the highlights from Align's Q1 update.

Hand holding clear aligner with reflection appearing on a table surface

Image source: Getty Images.

Below expectations

The company reported first-quarter revenue of $551 million. Not only was this result well below the average analysts' estimate of $580.3 million, but it also fell short of Align's guidance of revenue between $615 million and $630 million. Of course, that outlook was given before the COVID-19 outbreak hit the U.S. and Europe with full force.

Align's Q1 revenue also reflected a 15% drop from the previous quarter. This decline resulted in large part from Invisalign case shipment volume tumbling 13% from Q4. In addition, the company's scanner and services revenue sank nearly 35% from the sequential quarter to $69.4 million.

The dismal revenue picture also impacted Align's bottom line. The company announced Q1 adjusted earnings of $57.9 million, or $0.73 per share. This was a steep decline from earnings of $1.25 per share in the prior-year period and $1.76 per share in the fourth quarter of 2019. 

As was the case with its top-line result, Align's Q1 earnings badly missed the consensus Wall Street earnings estimate of $1.00 per share. The company's earnings number also was much lower than its guidance range of adjusted earnings between $1.19 and $1.28.

On the other hand, Align's earnings based on generally accepted accounting principles (GAAP) looked great, at least at first glance. The company reported GAAP earnings of $1.52 billion, or $19.21 per share, compared to GAAP earnings of $0.89 per share in the prior-year period and $1.53 per share in the previous quarter. However, the improvement stemmed entirely from an income tax benefit of $1.46 billion in the first quarter of 2020.

Likely to get worse

Align Technology didn't provide guidance for its second quarter and withdrew its previous guidance for full-year 2020. The company stated that it couldn't estimate the impact that the COVID-19 pandemic might have on its operations and financial results.

It seems almost certain, though, that things will get worse for Align in the second quarter. CEO Joe Hogan noted that most Invisalign practices shut down and no longer saw patients in North America and Europe beginning in mid-March. These shutdowns are still in effect in many areas. 

Even if dental professionals resume operations in the next few weeks, Align will have experienced more than one month of significantly lower revenue in the second quarter. It's also uncertain how quickly dentists' and orthodontists' offices will reopen. And when they do reopen, it's possible that many patients will still delay visits.

This could especially be problematic for Align in North America. In 2019, around 56% of the company's Invisalign case shipments were in the Americas region.

Putting things in perspective

All of this sounds bleak for Align, but it's important to put things in perspective. Joe Hogan stated that the company's business was humming along early in 2020. He noted that through early March, most regions were performing better than the company's outlook and China was in line with its January guidance.

Even with the dismal performance in the first quarter, Invisalign case shipments actually increased 2.9% year over year. Net revenue was up slightly as well compared to the prior-year period.

Healthcare stocks like Align that rely on close interactions between healthcare professionals and patients will likely remain highly volatile for several more months. But as the worries about COVID-19 diminish, expect Align's financial performance -- and its stock -- to rebound nicely.

Keith Speights owns shares of Align Technology. The Motley Fool owns shares of and recommends Align Technology. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Align Technology Stock Quote
Align Technology
ALGN
$228.81 (-0.48%) $-1.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.